📊 CNMD Key Takeaways
Investment Thesis
CNMD demonstrates solid operational cash generation (FCF margin 11%) and healthy liquidity (2.14x current ratio), but faces significant headwinds including flat revenue growth, sharp net income decline (-64.5% YoY), and weakening profitability margins (net margin 3.4%). The company's leverage remains manageable at 0.81x debt-to-equity, though deteriorating earnings quality requires monitoring of operational execution and market demand.
CNMD Strengths
- Strong free cash flow generation of $150.9M with 11% FCF margin indicates robust operational efficiency
- Solid liquidity position with 2.14x current ratio and quick ratio of 1.01x supports financial stability
- Healthy gross margin of 54.6% reflects underlying product competitiveness and pricing power in medical device market
- Moderate leverage at 0.81x debt-to-equity with 3.3x interest coverage provides financial flexibility
CNMD Risks
- Revenue stagnation at 1.4B with 0% YoY growth signals market saturation or competitive pressure in electromedical apparatus segment
- Severe net income decline of -64.5% YoY and sharp drop in diluted EPS to $1.51 indicate operational challenges or non-recurring charges requiring clarification
- Deteriorating net margin of 3.4% reflects compressed profitability despite stable gross margins, suggesting rising operating expenses or tax burden
- Low ROE of 4.6% and ROA of 2.0% indicate inefficient capital deployment relative to equity and asset base
- Minimal cash position of $40.8M relative to $1.3B liabilities limits financial flexibility for strategic investments or downturns
Key Metrics to Watch
- Revenue growth acceleration - must demonstrate organic growth resumption to validate market demand
- Net income trajectory - critical to understand whether -64.5% decline is temporary or structural
- Operating margin stability - monitor if 7.5% margin holds or continues compressing
- Free cash flow sustainability - validate that $150.9M FCF can be maintained with current capital efficiency
- Debt reduction progress - track deleveraging toward lower debt-to-equity given low profitability
CNMD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.14x current ratio provides a solid financial cushion.
CNMD Profitability Ratios
CNMD vs Healthcare Sector
How CONMED Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CNMD Balance Sheet & Liquidity
CNMD 5-Year Financial Trend
5-Year Trend Summary: CONMED Corp's revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.04 reflects profitable operations.
CNMD Growth Metrics (YoY)
CNMD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $316.7M | $2.9M | $0.09 |
| Q2 2025 | $332.1M | $21.4M | $0.69 |
| Q1 2025 | $312.3M | $6.0M | $0.19 |
| Q3 2024 | $304.6M | $15.8M | $0.50 |
| Q2 2024 | $317.7M | $13.7M | $0.43 |
| Q1 2024 | $295.5M | $1.8M | $0.06 |
| Q3 2023 | $275.1M | $15.8M | $0.50 |
| Q2 2023 | $277.2M | $13.7M | $0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CNMD Capital Allocation
CNMD SEC Filings
Access official SEC EDGAR filings for CONMED Corp (CIK: 0000816956)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNMD
What is the AI rating for CNMD?
CONMED Corp (CNMD) has an AI rating of HOLD with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNMD's key strengths?
Strong free cash flow generation of $150.9M with 11% FCF margin indicates robust operational efficiency. Solid liquidity position with 2.14x current ratio and quick ratio of 1.01x supports financial stability.
What are the risks of investing in CNMD?
Revenue stagnation at 1.4B with 0% YoY growth signals market saturation or competitive pressure in electromedical apparatus segment. Severe net income decline of -64.5% YoY and sharp drop in diluted EPS to $1.51 indicate operational challenges or non-recurring charges requiring clarification.
What is CNMD's revenue and growth?
CONMED Corp reported revenue of $1.4B.
Does CNMD pay dividends?
CONMED Corp pays dividends, with $24.7M distributed to shareholders in the trailing twelve months.
Where can I find CNMD SEC filings?
Official SEC filings for CONMED Corp (CIK: 0000816956) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNMD's EPS?
CONMED Corp has a diluted EPS of $1.51.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.